You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Glenmark Pharma rises after USFDA nod for generic acne treatment gel

Business Finance

Capital Market 

Glenmark Pharmaceuticals rose 1.40% to Rs 290.60 after the company said it received abbreviated new drug application approval for Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for adapalene and benzoyl peroxide gel, 0.10/012.5%, the generic version of Epiduo Gel, 0.1%/2.5%, of Galderma Laboratories L.P.

Adapalene and benzoyl peroxide are topical agents used for the treatment of acne vulgaris (pimples).

According to IQVIA sales data for the 12 month period ending September 2019, the Epiduo Gel, 0.10/012.5% market achieved annual sales of approximately $33.7 million.

Glenmark's current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. The announcement was made during trading hours today, 11 November 2019.

Shares of Glenmark Pharmaceuticals fell 9.64% in three trading sessions to settle at Rs 286.60 on Friday, 8 November 2019, from its close of Rs 317.20 on 5 November 2019.

Glenmark Pharmaceuticals' consolidated net profit slumped 53.1% to Rs 317.20 crore on 7.2% increase in net sales to Rs 2,283.60 crore in Q2 June 2019 over Q2 June 2018.

Glenmark Pharmaceuticals is a research‐driven, global, integrated pharmaceutical organization.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 11 2019. 15:20 IST